<DOC>
	<DOC>NCT00795418</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mid Alzheimer's disease</brief_summary>
	<brief_title>Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male and/or female patients between 40 and 85 years of age (both inclusive) Diagnosis of mild Alzheimer's Disease (AD) MiniMental State Examination (MMSE) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks. Previously participated in an AD vaccine study and received active treatment. History or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition. History or presence of seizures and/or cerebrovascular disease. Presence of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression) Advanced, severe, progressive or unstable disease that might interfere with the safety of the patient. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Neurodegenerative diseases</keyword>
</DOC>